La tirzepatida se vende bajo dos marcas diferentes: Zepbound y Mounjaro
The exact concentration depends on the cell type and the research question
[8] That is the design thesis behind retatrutides unusually large weight-loss figures and also behind its distinctive side-effect signal, discussed below

Why Retatrutide Might Differ There are theoretical reasons to believe retatrutide's triple-agonist mechanism could produce a more favorable body composition outcome than GLP-1-only drugs: The glucagon hypothesis Glucagon receptor activation unique to retatrutide among advanced clinical candidates has several effects that could preferentially target fat over muscle: Promotes lipolysis the breakdown of stored fat for energy, potentially directing the body to draw more energy from fat stores rather than muscle Increases thermogenesis energy expenditure through heat production, primarily in brown and beige adipose tissue, not muscle tissue Increases hepatic fatty acid oxidation the liver burns more fat, reducing liver fat stores If these mechanisms shift the body's energy sourcing toward fat metabolism, the proportion of weight lost from lean tissue could theoretically be lower with retatrutide than with drugs that lack glucagon activity

Without insurance, the typical retail cost for Ozempic is as high as $1,800 a month, while the price for Wegovy without insurance can range from $1,349 to over $1,800 a month
These changes correlate with the weakened circadian signals (for instance, a dampened melatonin rhythm and blunted nighttime drop in body temperature) that normally consolidate sleep at night